StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
YATHARTH.NS$792.85-2.06%
Fair $792.85+0.0%

YATHARTH.NS

Yatharth Hospital & Trauma Care Services Limited

Healthcare / Medical Care FacilitiesNSE

$792.85

-16.75 (-2.06%)

Fairly Valued+0.0%Fair Value $792.85Fund rank 24/100 · Data gapFallback financials|
SA 56/C
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-1.1B · quality 43.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 5/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

56/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · YATHARTH.NSLocal privado en este navegador · Yatharth Hospital & Trauma Care Services Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$76.4B

P/E

43.7x

↑

EV/EBITDA

24.2x

↑

ROE

9.8%

↑

Gross Margin

61.1%

↑

Debt/Equity

0.15

↓
52-Week Range$793
$485$890

TradingView lightweight chart

YATHARTH.NS price, volumen y niveles de valoración

Último $796.50Periodo +138.6%
Fair value: $792.85

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+32.4%

FCF CAGR

—

FCF margin

-9.3%

FCF / Net income

-0.64x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $12.07B · net income $1.75B · FCF $-1.12B

2023-FY → 2026-FY

Gross margin

61.1%-21.0% pts

Operating margin

16.9%-3.8% pts

Net margin

14.5%+1.9% pts

FCF margin

-9.3%-17.7% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$12.07B$12.07B$8.86B$6.71B$5.20B
Net Income$1.75B$1.75B$1.31B$1.14B$657.7M
EBITDA$3.18B$3.18B$2.36B$1.96B$1.37B
EPS——14.7214.467.66
Gross Margin61.1%61.1%61.7%80.1%82.1%
Operating Margin16.9%16.9%19.0%22.8%20.7%
Net Margin14.5%14.5%14.7%17.1%12.6%
Balance Sheet
Debt/Equity0.150.150.010.101.46
Current Ratio3.873.87———
Cash Flow
Free Cash Flow$-1.12B$-1.12B$-1.71B$-964.4M$439.7M
Returns
ROE9.8%9.8%8.1%13.1%35.9%
Valuation
P/E43.6643.6630.6931.65—
EV/EBITDA24.1724.1716.1318.57—
P/B4.294.292.504.15—
Growth & Yield
Revenue Growth36.3%36.3%32.1%28.9%—
EPS Growth——1.8%88.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +55.1%

Total return

+55.1%

Start / end P/E

n/dx → n/dx

EPS bridge

14.72 → n/d

Residual

+55.1%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+55.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.